Jump to:
Ana Gomez-Palazzo practices in the intellectual property transactions and life sciences groups at Ropes & Gray, advising clients on a wide range of strategic transactions, including license agreements, complex collaborations, mergers and acquisitions, supply and distribution agreements, and other commercial transactions where intellectual property is a key consideration.
Experience
- Advised Ionis Pharmaceuticals:
- in a collaboration agreement with Otsuka Pharmaceutical Co. Ltd, under which Otsuka obtains exclusive rights across the Europe and Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema, including a $65 million upfront payment for the European rights and a subsequent $20 million upfront payment for the Asia rights and milestone payments based on achievement of regulatory and sales targets, as well as eligibility to earn tiered royalties.
- in a $3.5 billion collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ antisense medicine for the treatment of transthyretin amyloidosis protein.
- Represented Fulcrum Therapeutics in a collaboration and license agreement with French pharmaceutical company Sanofi, valued at up to $1.05 billion, for the development and commercialization of losmapimod, an oral therapy being investigated for the treatment of the rare disease facioscapulohumeral muscular dystrophy (FSHD).
- Advised Ovid Therapeutics in a collaboration with Graviton Bioscience, under which Ovid obtained exclusive rights to develop ROCK2 inhibitors, including GV101, for a range of rare neurological diseases outside of greater China.
- Represented Pfizer Inc. in a $1.24 billion dollar ex-U.S. strategic collaboration agreement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as Nurtec ODT for the acute treatment of migraine attacks and the preventative treatment of episodic migraines.
- Represented Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a $1 billion dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs, two of which are in Phase 3 development.
- Advised Belgian biopharmaceutical company iTeos Therapeutics in a $2 billion collaboration with global health care leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal antibody as a potential treatment for cancer patients.
- Represented a global biopharmaceutical company in its collaboration, option and license agreement with a clinical stage biotechnology company to research and develop a vaccine-based immunotherapy for human immunodeficiency virus (HIV) infection.
- Advised Gilead Sciences, Inc. on intellectual property/licensing matters related to its $1.55 billion exclusive option to acquire Tizona Therapeutics, Inc.
- Represented Ginkgo Bioworks in a number of transactions, including a strategic partnership with Aldevron to optimize production of vaccinia capping enzymes (VCE).
- Advised Bain Capital in its $125 million non-dilutive financing with Cerevel Therapeutics to fund the Phase 3 development program for tavapadon in Parkinson's disease, also known as the TEMPO trials.